Synonym
KVD-900, K-VD-900, Sebetralstat; Sebetralstat free base;
IUPAC/Chemical Name
N-[(3-Fluoro-4-methoxypyridin-2-yl)methyl]-3-methoxy-1-({4-[(2-oxo-1,2-dihydropyridin-1-yl)methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide
InChi Key
QTNIRGIZAWMZRE-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H24FN5O4/c1-34-21-10-11-27-20(23(21)26)13-28-24(33)19-16-31(29-25(19)35-2)15-18-8-6-17(7-9-18)14-30-12-4-3-5-22(30)32/h3-12,16H,13-15H2,1-2H3,(H,28,33)
SMILES Code
O=C(C1=CN(CC2=CC=C(CN3C=CC=CC3=O)C=C2)N=C1OC)NCC4=NC=CC(OC)=C4F
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Hereditary angioedema (HAE) is a rare genetic disorder in which patients experience sudden onset of swelling in various locations of the body. HAE is associated with uncontrolled plasma kallikrein (PKa) enzyme activity and generation of the potent inflammatory mediator, bradykinin, resulting in episodic attacks of angioedema.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
477.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Davie RL, Edwards HJ, Evans DM, Hodgson ST, Stocks MJ, Smith AJ, Rushbrooke LJ, Pethen SJ, Roe MB, Clark DE, McEwan PA, Hampton SL. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema. J Med Chem. 2022 Oct 27;65(20):13629-13644. doi: 10.1021/acs.jmedchem.2c00921. Epub 2022 Oct 17. PMID: 36251573; PMCID: PMC9620001.
2: Mutch P, Bashir M, Jung B, Yi P, Iverson M. Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900) following a single oral dose in healthy male participants. Xenobiotica. 2022 Jul;52(7):707-717. doi: 10.1080/00498254.2022.2132187. Epub 2022 Oct 17. PMID: 36200371.
3: Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP. Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. Clin Exp Allergy. 2022 Sep;52(9):1059-1070. doi: 10.1111/cea.14122. Epub 2022 Mar 20. PMID: 35278245; PMCID: PMC9544254.
4: Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM. KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results. J Allergy Clin Immunol. 2022 Jun;149(6):2034-2042. doi: 10.1016/j.jaci.2021.10.038. Epub 2022 Jan 24. PMID: 35086692.
